FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Amado Rafael					<u>P</u>	2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) 5 ASHWOOI	(First)	(Middle)				3. Date of Earliest Transaction (Month/Day/Year) 01/04/2019								X	Officer (gi below)	resident, R & l		below)	<i>'</i>	
(Street) MALVERN (City)	PA (State		19355 (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual Line)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,						urities Ac sed Of (D		r. 3, 4				Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount (A)		A) or D)	Price :	Reported Transaction(s) (Instr. 3 and 4)		(111301. 4)		(msu. 1)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution any (Month/D	Date, if	8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount Securities Underlying Derivative Security (I 4)		/ing	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	e es ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expir Date	ation	Title		Amount or Number of Shares		Transact (Instr. 4)	ion(s)			
Option to purchase Ordinary Shares	\$0.89 ⁽¹⁾	01/04/2019			A		1,006,224		(2)	01/0	4/2029	Ordina Share		1,006,224	\$0	1,006,2	224	D		
Option to purchase Ordinary Shares	\$0.0013 ⁽³⁾	01/04/2019			A		224,724		(4)		(5)	Ordina Share		224,724	\$0	224,7	24	D		

Explanation of Responses:

- 1. The exercise price was converted from GBP0.70 based on an exchange rate of \$U.S. 1.26332 GBP1.00. The actual exercise price will be the pounds sterling amount.
- 2. Exercisable as to 251,556 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in monthly installments of 20,958 Ordinary Shares on the fourth of each month from February 4, 2020 through December 4, 2022 and 21,138 Ordinary Shares on January 4, 2023.
- 3. The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of \$U.S. 1.26332 GBP1.00. The actual exercise price will be the pounds sterling amount.
- 4. Exercisable as to 56,178 Ordinary Shares on January 4, 2020 and will be exercisable as to the remainder in annual installments of 56,178 Ordinary Shares on January 4, 2021 and January 4, 2022 and 56,190 Ordinary Shares on January 4, 2023.
- 5. The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

/s/ Rafael Amado 01/08/2019
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.